Last reviewed · How we verify
Ncardipine Hydrochloride Injection
Nicardipine hydrochloride is a dihydropyridine calcium channel blocker that inhibits calcium influx into vascular smooth muscle cells, causing vasodilation and reducing blood pressure.
Nicardipine hydrochloride is a dihydropyridine calcium channel blocker that inhibits calcium influx into vascular smooth muscle cells, causing vasodilation and reducing blood pressure. Used for Acute hypertension management, Hypertensive emergency.
At a glance
| Generic name | Ncardipine Hydrochloride Injection |
|---|---|
| Sponsor | Nanjing Yoko Biomedical Co., Ltd. |
| Drug class | Dihydropyridine calcium channel blocker |
| Target | L-type voltage-gated calcium channel |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Nicardipine selectively blocks L-type calcium channels in vascular smooth muscle, preventing calcium-dependent contraction and leading to peripheral vasodilation. This results in reduced systemic vascular resistance and blood pressure lowering. The intravenous formulation provides rapid onset of action suitable for acute hypertensive episodes.
Approved indications
- Acute hypertension management
- Hypertensive emergency
Common side effects
- Headache
- Flushing
- Tachycardia
- Dizziness
- Hypotension
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: